Using machine learning tools to detect gene mutations from leukemia cell images
Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...
pharmaphorum6d
EHA: Survival data sets Daiichi Sankyo's quizartinib back on track
Three years after Daiichi Sankyo's FLT3 inhibitor quizartinib was rejected by the FDA, the drugmaker has reported the results of a new phase 3 trial that is key to getting the drug to the US ...
Hosted on MSN11mon
ABT199/Venetoclax synergism with thiotepa in acute myeloid leukemia (AML) cells
Moreover, this combination is active against P53-negative and FLT3-ITD-positive cell lines. Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the ...
Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath ...
pharmaphorum1d
Merck drug for rare tumour hits phase 3 target
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT ... KIT, and FLT3 inhibitor that was cleared for TGCT by the FDA in ...
Nature3y
KScan: personalizing medicine with phosphoproteomics
Midostaurin, which targets the FLT3 receptor (WT and/or mutant), was ... Preclinical studies with cancer cells derived from AML patients treated with midostaurin ex vivo demonstrated that ...
Medscape4d
Clinical Overview of Sorafenib in Breast Cancer
Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and ... of advanced renal cell carcinoma and unresectable ...